Objective-Revealing patterns of associations between circulating protein and lipid levels could improve biological understanding of cardiovascular disease (CVD). In this study, we investigated the associations between proteins related to CVD and triglyceride (TG), total cholesterol, LDL (low-density lipoprotein), and HDL (high-density lipoprotein) cholesterol levels in individuals from the general population. Approach and Results-We measured plasma protein levels using the Olink ProSeek CVD I or II+III arrays and analyzed 57 proteins available in 3 population-based cohorts: EpiHealth (n=2029; 52% women; median age, 61 years), PIVUS (Prospective Study of the Vasculature in Uppsala Seniors; n=790; 51% women; all aged 70 years), and ULSAM (Uppsala Longitudinal Study of Adult Men; n=551; all men aged 77 years). A discovery analysis was performed in EpiHealth in a regression framework (adjusted for sex, age, body mass index, smoking, glucose levels, systolic blood pressure, blood pressure medication, diabetes mellitus medication, and CVD history), and associations with false discovery rate <0.05 were further tested in PIVUS and ULSAM, where a P value of 0.05 was considered a successful replication (validation false discovery rate of 0.1%). We used summary statistics from a genome-wide association study on each protein biomarker (meta-analysis of EpiHealth, PIVUS, ULSAM, and IMPROVE [Carotid Intima-Media Thickness and IMT-Progression as Predictors of Vascular Events in a High-Risk European Population]) and publicly available data from Global Lipids Genetics Consortium to perform Mendelian randomization analyses to address possible causality of protein levels. Of 57 tested proteins, 42 demonstrated an association with at least 1 lipid fraction; 35 were associated with TG, 15 with total cholesterol, 9 with LDL cholesterol, and 24 with HDL cholesterol. Among these associations, we found KIM-1 (kidney injury molecule-1), TNFR (TNF [tumor necrosis factor] receptor) 1 and 2, TRAIL-R2 (TRAIL [TNFrelated apoptosis-inducing ligand] receptor 2), and RETN (resistin) to be associated with all 4 lipid fractions. Further, 15 proteins were related to both TG and HDL cholesterol in a consistent and biologically expected manner, that is, higher TG and lower HDL cholesterol or vice versa. Another common pattern of associations was concomitantly higher TG, total cholesterol, and LDL cholesterol, which is associated with higher CVD risk. We did not find evidence of causal links for protein levels. fatty acid pool. 3, 4 Similarly, GH (growth hormone), in addition to its primary function to control and promote skeletal growth, also stimulates lipolysis in adipose tissue, resulting in increased free fatty acid levels in the blood.
T riglycerides (TG), total cholesterol (TC), LDL (low-density lipoprotein) cholesterol (LDL-C), and HDL (high-density lipoprotein) cholesterol (HDL-C)-important lipid fractions-attract clinical attention when present in abnormal concentrations. This is not only because of their strong association with coronary heart disease-the leading cause of death worldwide-but increased TG and decreased HDL-C are also key metabolic abnormalities in patients with obesity, insulin resistance (IR), and type 2 diabetes mellitus, 1 increasing public health burdens.
Central roles of lipids in physiology and disease and their metabolic and signaling functions often arise from interactions with proteins. 2 For instance, FABP4 (fatty acid-binding protein 4) acts as a cytoplasmic lipid chaperone, suppressing adipose tissue lipogenesis and promoting lipolysis, with direct effects on the composition of the local and circulating free fatty acid pool. 3, 4 Similarly, GH (growth hormone), in addition to its primary function to control and promote skeletal growth, also stimulates lipolysis in adipose tissue, resulting in increased free fatty acid levels in the blood. 5 KIM-1 (kidney injury molecule-1) is a phosphatidylserine receptor that recognizes apoptotic cells and directs them to lysosomes but also serves as a receptor for oxidized lipoproteins. 6 Recent advances in highly multiplexed immunoassays allow measuring simultaneously a wide range of plasma proteins selected for their role in cardiovascular disease (CVD), thus facilitating studies of the broad picture of lipid-protein associations in the circulatory system, which may provide valid nodes for drug action to treat human diseases.
Observational epidemiological studies provide a wealth of information on associations between disease exposures and outcomes, but these relations should not be interpreted as causal, owing to limitations introduced by confounding and reverse causality. 7 Mendelian randomization (MR) is a method using genetic variants as instrumental variables to assess causal relationships from observational data. 8 Thus, this design excludes possibility of reverse causation, and under certain assumptions, MR methods also avoid confounding. 8 The primary aim of this study was to evaluate associations of circulating proteins with lipid fractions in several population-based cohorts. In addition, we investigated causal effects of protein levels on lipid levels using MR methods, as well as used different orthogonal data sources to increase biological understanding of associations between circulating plasma proteins and lipids.
Methods
Data are made available to researchers who meet the criteria for confidential data access as stipulated by participant informed consent and institutional review board. Data access in ULSAM (Uppsala Longitudinal Study of Adult Men) is granted through the Interdisciplinary Collaboration Team on Uppsala Longitudinal Studies (http://www.pubcare.uu.se/ulsam/Research/Proposals). Data from the PIVUS (Prospective Study of the Vasculature in Uppsala Seniors) are available after application to the PIVUS steering committee (http://www.medsci.uu.se/pvus/). Data from the EpiHealth study are granted after application to the EpiHealth steering committee (http://www.epihealth.se/For-scientists/Research-Application-/).
Study Samples

EpiHealth
The EpiHealth study was initiated in 2011 with the goal of recruiting 300 000 men and women aged 45 to 75 years in the Swedish towns of Uppsala and Malmö. 9 The study consists of 3 parts: a collection of self-reported data on lifestyle by internet-based questionnaires, a clinical visit where blood samples are collected and physiological parameters recorded, and follow-up for occurrence of outcomes using nationwide medical registers. The present study is based on a random sample of 2467 individuals with measured protein profile. Of this sample, 7 individuals were excluded because of unsuccessful protein profiling (not passing the quality control), 141 because of fasting time <6 hrs, 240 because of being on lipid-lowering medication, and 50 because of missing information on covariates used in the main analysis; thus, leaving 2029 individuals for the main analysis (Table 1) .
Prospective Study of the Vasculature in Uppsala Seniors
The PIVUS study has been described previously 10 and on the internet (www.medsci.uu.se/pivus/pivus.htm). All 70-year-old individuals residing in Uppsala, Sweden, in 2001 to 2005 were eligible for the study, and 2025 individuals were invited in a randomized order within 2 months of their 70th birthday. Of these, 1016 (50.2%) participated, and 510 (50.2%) of them were women. We excluded 25 individuals because of unsuccessful protein profiling, 21 individuals because of CRP (C-reactive protein) levels above 20 mg/L (to exclude individuals with possible ongoing infection and other inflammatory processes), 154 because of being on lipid-lowering medication, and 26 individuals because of missing information on covariates in the main analysis. Hence, the eligible sample size for the present study was 790 individuals (Table 1) .
Uppsala Longitudinal Study of Adult Men
The ULSAM has been described previously 11 and on the internet (http://www.pubcare.uu.se/ulsam). The study was initiated in the Nonstandard Abbreviations and Acronyms
CCL3
C-C motif chemokine 3 
Lipid Measurement
In EpiHealth, at the test center, 10 mL of the blood sample was used for determinations of fasting glucose, LDL-C and HDL-C, and TG at the hospital laboratory using an Architect Ci8200 analyzer (Abbott Laboratories, Abbott Park, IL). 9 In PIVUS, lipid variables were measured by standard laboratory techniques at the Uppsala University Hospital. 10 In ULSAM, cholesterol and TG concentrations were analyzed in serum and isolated lipoprotein fractions by enzymatic techniques using IL Test Cholesterol Trinder Method 181618-10 and IL Test Triglyceride Enzymatic-Colorimetric Method 181610-60 for use in a Monarch apparatus (Instrumentation Laboratories, Lexington, MA). HDL particles were separated by precipitation with magnesium chloride and phosphotungstate. LDL-C was calculated using Friedewald formula.
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Other Covariates
Anthropometric measures (height and weight) of PIVUS, ULSAM, and EpiHealth participants were recorded at the time of blood draw used for proteomic analysis and were measured by trained staff. For PIVUS and ULSAM, medical history, smoking habits, and regular medication were collected at the time of blood draw by self-administered questionnaires or interviews by a study nurse and national registries. The same data for EpiHealth were collected before the clinical visit by internet-based questionnaires or by national registries.
Proteomic Analysis
Proteomic profiling in EpiHealth was performed using the Olink Proseek Multiplex CVD II and III 96×96 kits (http://www.olink.com/ products/cvd-ii-panel/ and http://www.olink.com/products/cvd-iiipanel/) measuring 92 selected CVD-related proteins simultaneously. The kits are based on the proximity extension assay technology, where 92 oligonucleotide-labeled antibody probe pairs are allowed to bind to their respective target present in the sample. The proximity extension assay technique shows exceptionally high specificity and sensitivity. 13, 14 The platform provides normalized protein expression data where a high protein value corresponds to a high protein concentration but not an absolute quantification. Samples that (1) failed for technical reasons on both chips or (2) a sample call rate <0.95 on either chip were excluded. Proteins with ≥10% missingness were also excluded. Each protein was normalized by plate (by setting the mean as 0 and SD as 1 within each plate).
Details on PIVUS and ULSAM blood samples have been described previously. 15, 16 Analyses were performed using the Olink Proseek Multiplex CVD I 96×96 kit (http://www.olink.com/products/ document-download-center/). All samples and runs for PIVUS and ULSAM passed technical quality control. Twelve proteins with a call rate <85% (ie, <85% of the individuals had a valid measurement of that specific protein) in PIVUS or ULSAM were removed from further analysis, including IL-4 (interleukin), melusin, BNP (B-type natriuretic peptide), β-NGF (beta-nerve growth factor), SIRT2 (SIR2-like protein 2), NEMO (NF-kappa-B essential modulator), mAmP (Xaa-Pro aminopeptidase 2), PTX3 (pentraxin-related protein), NT-proBNP (N-terminal pro-B-type natriuretic peptide), MMP (matrix metalloproteinase)-7, cystatin-B, and heat shock 27 kDa protein. Individuals with excess missingness based on visual inspection of a histogram were excluded (>5% and >3% in PIVUS and ULSAM, respectively). Each protein was normalized by plate and further by storage time (correction based on the observed values and predicted values from a spline model). We analyzed 57 proteins that overlapped between the CVD I, II, and III arrays and that passed quality control in all 3 cohorts. The full lists of analyzed proteins are presented in Table I in the online-only Data Supplement.
Statistical Analysis Primary Analysis
We evaluated the distribution of protein values and clinical covariates using the Shapiro-Wilk normality test and QQ plots. All protein and lipid variables were normalized by rank transformation. The EpiHealth study was a priori designated as the discovery cohort because it was the largest and had equal proportions of men and women. Linear regression models were used for all analyses. Lipid levels were used as the independent variables, and the 57 proteins were used as dependent variables in separate models (1 per lipid fraction and protein marker). The analysis of the protein profiling data was performed in an age-and sex-adjusted model (only age in ULSAM because all participants were men) and a multivariable-adjusted model. We considered the multivariable-adjusted models as our main models, both when deciding which protein markers to pursue for replication and which to annotate as significantly associated. The multivariableadjusted model included age, sex, body mass index, smoking (a factor variable with 3 levels: never, former, and current smoker), glucose levels, systolic blood pressure, antihypertensive medication, diabetes mellitus medication, and prior myocardial infarction, angina, stroke, heart failure, and atrial fibrillation. Prior CVDs were defined by self-report (EpiHealth and ULSAM) or the International Classification of Diseases codes (ULSAM). Protein markers with a false discovery rate (estimated using the Benjamini-Hochberg method) 17 <5% in EpiHealth were selected for further replication in PIVUS and ULSAM. Study-specific estimates from PIVUS and ULSAM were combined using an inverse variance-weighted mixed-effects meta-analysis, and associations with the same direction as in EpiHealth at P value <0.05 were considered successful replication. We have previously shown that this replication strategy is conservative, and indeed, the risk of false-positive findings in the replication stage (validation false discovery rate) was calculated to 0.1% for each lipid fraction separately (http://fafner.meb.ki.se/personal/yudpaw/ rdr/). 18 The study design is depicted in Figure 1 .
Orthogonal Data Sources
We queried Search Tool for the Retrieval of Interacting Genes/ Proteins (STRING) 19 for protein-protein interaction networks, filtering on an interaction score of strong evidence (0.7). Then, we used data from the Genotype-Tissue Expression (GTEx) project 20 to depict expression patterns in physiologically relevant tissues, specifically whole blood (because the protein biomarkers in our study were measured in blood samples); coronary artery, aorta, tibial artery, heart left ventricle, and heart atrial appendage (representing cardiovascular system since the protein biomarkers were selected based on their relation to CVD); and subcutaneous adipose tissue, visceral adipose tissue, liver, and skeletal muscle (tissues involved in lipid metabolism and IR). Finally, we searched Catalog of published genome-wide association studies (GWAS; GWAS Catalog) 21 inquiring gene names corresponding to protein biomarkes. This allowed us to find associations in GWAS (P<5×10 −8 ) if variants were mapped to the inquired genes or the inquired genes were in the neighborhood of associated loci.
Mendelian Randomization
In MR analyses, an association between a genetic instrument and the outcome is indicative of a causal effect of the risk factor on the outcome. 22 In this study, we performed two-sample MR analyses using genetic summary statistics where we tested the hypothesis that different protein levels affect lipid fractions. The analyses were performed for all lipid-protein associations that were replicated in the observational analyses.
Summarized Data Used in MR
GWAS, which typically report regression coefficients summarizing the associations of many genetic variants with various traits, are potentially a powerful source of data for MR investigations. 23 We used summary statistics from GWAS performed on each protein biomarker, as described in the study by Folkersen et al 24 ; but in the present study, we obtained results from a meta-analysis of EpiHealth, PIVUS, ULSAM, and IMPROVE (Carotid IntimaMedia Thickness and IMT-Progression as Predictors of Vascular Events in a High-Risk European Population; total number of subjects, n=7390). The IMPROVE study is a multicenter, observational study, which recruited 3711 men and women aged between 55 and 79 years with at least 3 cardiovascular risk factors but without symptoms of CVD. 25 The study was conducted in accordance with the declaration of Helsinki, and all participants gave written informed consent. The ethics and sampling of this cohort have been further documented in prior publications. 26 For lipid fractions, we used summary statistics data from Global Lipids Genetics Consortium-the largest (n=188 577), publicly available GWAS of lipid traits. 27 As instrumental variables, we selected all independent variants (r 2 <0.01) associated with protein levels at genomewide significant level (P<5×10 −8 ) and having cis effects on protein-coding gene expression, that is, variants in the same locus as the protein-coding gene (Table III in the online-only Data Supplement). Of the 42 proteins associated with at least 1 lipid fraction, we were able to create genetic instruments for 30 protein biomarkers. There were no genome-wide significant variants associated with GH and leptin; no cis single-nucleotide polymorphisms (SNPs) associated with levels of FGF-23 (fibroblast growth factor 23), IL-27, IL-6, MCP-1 (monocyte chemotactic protein 1), PDGF (platelet-derived growth factor) subunit B, SCF (stem cell factor), tPA (tissue-type plasminogen activator), VEGF-D (vascular endothelial growth factor D); and no proxies in the GWAS data on lipids in Global Lipids Genetics Consortium for variants associated with CD40L (cluster of differentiation 40 ligand) and FABP4 (presumably due to low minor allele frequency, 1.2% for the single variants associated with these proteins). For outcomes, we used data from the Global Lipids Genetics Consortium. 27 We used the Wald method when only 1 SNP was used as an instrument, whereas the inverse-variance weighted method was used for combinations of >1 variant. 28 All MR analyses were performed with the TwoSampleMR package in R, which allows evaluating the causal effect of an exposure on an outcome using only summary statistics from GWAS. 29 To minimalize risk of false-positive findings because of high number of tests, we applied Bonferroni correction of the nominal α-threshold of 0.05. Using an online tool (http:// sb452.shinyapps.io/power/), we estimated statistical power for the different MR analyses using the outcome sample sizes, effect sizes observed using traditional regression, variance explained for the instrumental variable, and the Bonferronicorrected P value, all specific for each analysis.
Results
The clinical characteristics of the study samples are presented in Table 1 . Compared to the EpiHealth (discovery cohort), the PIVUS and ULSAM populations were older and more likely to be taking antihypertensive and diabetes mellitus medication and have prior CVD. Also, importantly, ULSAM consisted exclusively of men.
Observational Analyses
Of 57 investigated protein biomarkers, 42 demonstrated a replicated association with at least 1 of the lipid fractions; 35 were associated with TG, 15 with TC, 10 with LDL-C, and 22 with HDL-C (Figures 2 and 3 ; Table 2 ). Among these associations, we found KIM-1, TNFR (TNF [tumor necrosis factor] receptor) 1 and 2, TRAIL-R2 (TRAIL [TNF-related apoptosis-inducing ligand] receptor 2), and RETN (resistin) to be associated with all 4 lipid fractions. Further, 15 proteins were related to both TG and HDL-C in a consistent and biologically expected manner, that is, higher TG and lower HDL-C or vice versa. Of these, SCF and GH represent a pattern generally associated with lower IR and CVD risk because they were associated with lower TG and higher HDL-C. FABP4, tPA, IL-1RA (IL-1 receptor antagonist protein), CCL3 (C-C motif chemokine 3), FGF-23, IL-16, IL-18, MMP-12, PlGF (placenta growth factor), RETN, TNFR1, TNFR2, and TRAIL-R2 were associated with higher TG and lower HDL-C, thus a pattern consistent with IR. Another common pattern of associations was concomitantly higher TG, TC, and LDL-C, which often is associated with higher CVD risk. This was observed for higher CXCL16 (C-X-C motif chemokine 16), Gal3 Gal3, galectin-3; GDF-15, growth/differentiation factor 15; GH, growth hormone; HB-EGF, heparin-binding EGF-like growth factor; HDL, high-density lipoprotein; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist protein; IL-6RA, interleukin-6 receptor subunit-α; KIM-1, kidney injury molecule-1; KLK6, kallikrein-6; LDL, low-density lipoprotein; LEP, leptin; LOX-1, lectin-like oxidized low-density lipoprotein receptor 1; MCP-1, monocyte chemotactic protein 1; MMP-12, matrix metalloproteinase-12; PDGF, platelet-derived growth factor; PlGF, placenta growth factor; PSGL-1, P-selectin glycoprotein ligand 1; REN, renin; RETN, resistin; SCF, stem cell factor; SELE, E-selectin; ST2, ST2 protein; TF, tissue factor; TM, thrombomodulin; TNFR1, tumor necrosis factor receptor 1; TNFR2, tumor necrosis factor receptor 2; tPA, tissue-type plasminogen activator; TRAIL-R2, tumor necrosis factor-related apoptosisinducing ligand; uPAR, urokinase plasminogen activator surface receptor; and VEGF-D, vascular endothelial growth factor D.
(galectin-3) and MCP-1. Moreover, there was a set of proteins that were associated only with TG, all of them in a positive fashion (Figure 2) . Results from the age-and sex-adjusted analyses are presented in Table I in the online-only Data Supplement. Overall, some associations from age-and sexadjusted model were no longer significant in the fully adjusted analyses (Table II in the online-only Data Supplement).
We performed additional bioinformatics analyses of the 5 proteins associated with all lipid fractions. Four of them, TNFR1, TNFR2, TRAIL-R2, and RETN, displayed protein-protein interactions with high confidence (probability of 0.7) according to the STRING database. These interactions included interactions from curated databases of biological pathway knowledge, such as Kyoto Encyclopedia of Genes and Genomes, interactions determined in experiments, coexpression, and protein homology (Figure 4) . TNFR1, TNFR2, and TRAIL-R2 share some of the functional partners, including TRADD (TNFRSF1A associated via death domain), which is involved in apoptosis modulation and signaling; RIPK-1 (receptor interacting serine/threonine kinase 1) that plays a role in inflammation and cell death in response to tissue damage; and TRAF2 (TNFR-associated factor 2), which plays a central role in the regulation of cell survival and apoptosis. The only partner for RETN identified by STRING was NR3C1 (nuclear receptor subfamily 3, group C, member 1)-a glucocorticoid receptor; whereas there were no functional partners identified for KIM-1. TNFRSF1A, TNFRSF1B, and TNFRSF10B, encoding for TNFR1, TNFR2, and TRAIL-R2, respectively, are expressed in whole blood, coronary artery, aorta, tibial artery, heart left ventricle, heart atrial appendage, subcutaneous and visceral adipose tissue, liver, and skeletal muscle, whereas RETN is detected mostly in the whole blood ( Figure 5 ). There is no expression of HAVCR1 encoding for KIM-1 in the examined tissues. GWAS results from previous studies show that intronic variant rs1553318 in HAVCR1 and intergenic SNPs in the HAVCR1 locus (rs6882076 and rs1501908) have been associated with TG, TC, and LDL-C levels, which is consistent with our findings from observational analyses. Intronic variants in TNFRSF1A (rs1800693, rs4149576, rs2284344, rs4149577, and rs1860545) have been associated with autoimmune and inflammatory diseases, such as multiple sclerosis, primary biliary cirrhosis, or ankylosing spondylitis. A variant mapped to the chromosome region of TNFRSF1B has been associated with tuberculosis, and a variant mapped to the TNFRSF10B locus (encoding for TRAIL-R2) has been associated with renal cell carcinoma. A variant rs1423096 in 3′-region of RETN, which is also in high linkage disequilibrium with variation in the promoter of RETN, and variant rs3219175 in 5′ near RETN, have been associated with RETN levels (Table IV in the online-only Data Supplement).
Mendelian Randomization
The number of SNPs included in each instrument is indicated in Table 3 . In total, we performed 59 tests in these MR analyses (many of the 30 proteins were associated with several lipid Figure 3 . Directions of the associations between protein biomarkers and lipid levels. Effects for protein levels are given for a 1-SD increase in lipid levels. *Significant associations. AM indicates adrenomedullin; CCL3, C-C motif chemokine 3; CD40L, cluster of differentiation 40 ligand; CTSD, cathepsin D; CXCL16, C-X-C motif chemokine 16; DKK-1, Dickkopf-related protein 1; FABP4, fatty acid-binding protein 4; FAS, tumor necrosis factor receptor superfamily member 6; FGF-23, fibroblast growth factor 23; Gal3, galectin-3; GDF-15, growth/ differentiation factor 15; GH, growth hormone; HB-EGF, heparin-binding EGF-like growth factor; HDL, high-density lipoprotein; IL-1RA, interleukin-1 receptor antagonist protein; IL-6RA, interleukin-6 receptor subunit-α; IL27-A, interleukin-27 subunit-α; KIM-1, kidney injury molecule-1; KLK6, kallikrein-6; LDL, low-density lipoprotein; LEP, leptin; LOX-1, lectin-like oxidized low-density lipoprotein receptor 1; MCP-1, monocyte chemotactic protein 1; MMP-12, matrix metalloproteinase-12; PDGF, platelet-derived growth factor; PlGF, placenta growth factor; PSGL-1, P-selectin glycoprotein ligand 1; REN, renin; RETN, resistin; SCF, stem cell factor; SELE, E-selectin; ST2, ST2 protein; TC, total cholesterol; TF, tissue factor; TG, triglyceride; TM, thrombomodulin; TNFR1, tumor necrosis factor receptor 1; TNFR2, tumor necrosis factor receptor 2; tPA, tissue-type plasminogen activator; TRAIL-R2, tumor necrosis factor-related apoptosis-inducing ligand; and uPAR, urokinase plasminogen activator surface receptor. of the 59 analyses, we had >80% power to detect the effect size from the observational analyses (Table 3) .
Discussion
The aim of this study was to investigate the associations between circulating cardiovascular-related protein biomarkers and TGs, TC, LDL-C, and HDL-C. The data obtained from . Inquired proteins are depicted in red and interactions are shown for scores of strong evidence (the estimated likelihood of a given interaction being biologically meaningful, specific, and reproducible, given the supporting evidence is 0.7). ADAM17 indicates ADAM metallopeptidase domain 17; BIRC2, baculoviral IAP repeat containing 2; CASP8, caspase-8; CASP10, caspase-10; CFLAR, CASP8 and FADD-like apoptosis regulator; CHUK, conserved helix-loop-helix ubiquitous kinase; FADD, Fas (TNFRSF6)-associated via death domain; FASLG, Fas ligand; IKBKB, inhibitor of kappa light polypeptide gene enhancer in B-cells; LTA, lymphotoxin alpha; LTB, lymphotoxin beta; MAPK3K7, mitogen-activated protein kinase kinase kinase 7; NR3C1, nuclear receptor subfamily 3, group C, member 1; RIPK-1, receptor interacting serine/threonine kinase 1; TNF, tumor necrosis factor; TNFRSF1A, tumor necrosis factor receptor superfamily, member 1A; TNFRSF1B, tumor necrosis factor receptor superfamily, member 1B; TNFRSF10B, tumor necrosis factor receptor superfamily, member 10B; TNFSF10, tumor necrosis factor (ligand) superfamily, member 10; TRADD, TNFRSF1A associated via death domain; TRAF1, TNF receptor-associated factor 1; and TRAF2, TNF receptor-associated factor 2. AM indicates adrenomedullin; CCL3, C-C motif chemokine 3; CD40L, cluster of differentiation 40 ligand; CHI3L1, chitinase-3-like protein 1; CTSD, cathepsin D; CXCL16, C-X-C motif chemokine 16; DKK-1, Dickkopf-related protein 1; FABP4, fatty acid-binding protein 4; FAS, tumor necrosis factor receptor superfamily member 6; FGF-23, fibroblast growth factor 23; Gal3, galectin-3; GDF-15, growth/differentiation factor 15; GH, growth hormone; HB-EGF, heparin-binding EGF-like growth factor; HDL-C, high-density lipoprotein cholesterol; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist protein; IL-6RA, interleukin-6 receptor subunit-α; IL27-A, interleukin-27 subunit-α; KIM-1, kidney injury molecule-1; KLK6, kallikrein-6; LDL-C, low-density lipoprotein cholesterol; LEP, leptin; LOX-1, lectin-like oxidized lowdensity lipoprotein receptor 1; MCP-1, monocyte chemotactic protein 1; MMP-12, matrix metalloproteinase-12; PDGF, platelet-derived growth factor; PIVUS, Prospective Study of the Vasculature in Uppsala Seniors; PlGF, placenta growth factor; PSGL-1, P-selectin glycoprotein ligand 1; REN, renin; RETN, resistin; SCF, stem cell factor; SELE, E-selectin; ST2, ST2 protein; TC, total cholesterol; TF, tissue factor; TG, triglyceride; TM, thrombomodulin; TNFR1, tumor necrosis factor receptor 1; TNFR2, tumor necrosis factor receptor 2; tPA, tissue-type plasminogen activator; TRAIL-R2, tumor necrosis factor-related apoptosis-inducing ligand; ULSAM, Uppsala Longitudinal Study of Adult Men; uPAR, urokinase plasminogen activator surface receptor; and VEGF-D, vascular endothelial growth factor D.
*Adjusted for age, sex, BMI, smoking, glucose levels, systolic blood pressure, antihypertensive medication, diabetes mellitus medication and myocardial infarction, angina, stroke, heart failure, and atrial fibrillation. Figure 5 . Expression of genes encoding proteins associated with 4 lipid fractions in relevant tissues based on Genotype-Tissue Expression (GTEx) data. HAVCR1 is a gene encoding for KIM-1 (kidney injury molecule-1), TNFRSF1A encoding for TNFR1 (tumor necrosis factor receptor 1), TNFRSF1B encoding for TNFR2 (tumor necrosis factor receptor 2), and TNFRSF10B encoding for TRAIL-R2 (tumor necrosis factor-related apoptosis-inducing ligand). RETN indicates resistin; RPKM, reads per kilobase transcript per million reads; and TNFRSF10B, tumor necrosis factor receptor superfamily member 10B. AM indicates adrenomedullin; CCL3, C-C motif chemokine 3; CHI3L1, chitinase-3-like protein 1; CTSD, cathepsin; CXCL16, C-X-C motif chemokine 16; DKK-1, Dickkopf-related protein 1; FAS, tumor necrosis factor receptor superfamily member 6; Gal3, galectin-3; GDF-15, growth/differentiation factor 15; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist protein; IL-6RA, interleukin-6 receptor subunit-α; KIM-1, kidney injury molecule-1; LOX-1, lectin-like oxidized low-density lipoprotein receptor 1; MMP-12, matrix metalloproteinase-12; MR, Mendelian randomization; PlGF, placenta growth factor; PSGL-1, P-selectin glycoprotein ligand 1; RETN, resistin; SELE, E-selectin; SNP, single-nucleotide polymorphism; ST2, ST2 protein; TF, tissue factor; TM, thrombomodulin; TRAIL-R2, tumor necrosis factor-related apoptosisinducing ligand; and uPAR, urokinase plasminogen activator surface receptor.
3 Swedish populations provide a broad picture of lipid-protein associations in the circulatory system, showing among other things that KIM-1, TNFR1 and TNFR2, TRAIL-R2, and RETN were associated with all 4 lipid fractions. To the best of our knowledge, this study represents the most comprehensive analysis of the circulating lipid fractions and protein biomarkers. We studied a broad set of different proteins, such as cytokines, enzymes, growth factors, hormones, and receptors in healthy, general population. This is of great importance since it could provide ideas for possible strategies of intervention before CVD develop. Moreover, it is well established that alterations in glucose metabolism are strongly associated with CVD. 30 In the current study, we found 15 of the cardiovascular-related protein biomarkers to be associated with higher TG and lower HDL-C (or vice versa)-a phenotype reflecting IR.
Potential Biological Explanations to Our Observations
TNF-α-a proinflammatory cytokine produced mainly by macrophages-has the capacity to induce dyslipoproteinemia. [31] [32] [33] TNF-α exerts its action through 2 receptors, sTNFR (soluble TNFR) 1 and 2, both of which are expressed in membrane-bound form on the surface of most cells. 34 From the cell surface, both receptors are shed into the circulation, partly as a response to TNF. In inflammatory states, the levels of sTNFRs usually parallel the circulating levels of TNF. 34, 35 It has been shown that TNF-α decreases HDL-C levels, 36 which is in line with our results showing negative associations between HDL and TNFR1 and TNFR2. TG levels were associated with the activities of TNF-α, sTNFR1, and sTNFR2 in patients with systemic lupus erythematosus. 37 Thus, enhanced activity in the TNFα/TNFR system may be one underlying factor contributing to both dyslipoproteinemia and promotion of chronic inflammation not only in patients with systemic lupus erythematosus 37 but also in healthy individuals. TRAIL is a death ligand-a cytokine that activates apoptosis through cell surface death receptors. The levels of circulating TRAIL correlate with total body fat and serum lipid levels. 38 Its receptor TRAIL-R2 is expressed on the cellular surface of human preadipocytes and is still present in significant amounts on lipid-laden adipocytes. 39 In a previous study, activation of TRAIL-R2 with recombinant human TRAIL resulted in a robust inhibition of insulin-stimulated glucose uptake and insulin-stimulated de novo lipogenesis. 39 By binding to TRAIL-R2, TRAIL activates the cleavage of caspase-8 and caspase-3, which in turn cleaves and inactivates PPARγ (peroxisome proliferator-activated receptor-γ). This causes changes in gene expression of lipogenic genes and finally leads to the inhibition of insulin-stimulated glucose uptake and lipogenesis. In the current study, TRAIL-R2 levels were associated with higher TG levels but lower TC, LDL-C, and HDL-C levels.
KIM-1 is a phosphatidylserine receptor that recognizes apoptotic cells directing them to lysosomes. It also serves as a receptor for oxidized lipoproteins and hence is adept at recognizing apoptotic cell "eat me" signals. 40 In previous studies, higher urinary KIM-1 levels have been associated with increased risk for heart failure, lower insulin sensitivity, and higher risk of cardiovascular mortality. [41] [42] [43] In our study, circulating KIM-1 was associated with high levels of all 4 lipid fractions. RETN, named after its IR effect observed in mice after RETN injection, is produced and released from adipose tissue to serve endocrine functions. 44 In our study, it was associated with IR phenotype, that is, high TG and low HDL. RETN increases the production of LDL-C and also degrades LDL receptors in the liver, thus decreases liver's ability to clear LDL-C from circulation. 45 Moreover, RETN accelerates the accumulation of LDL in arteries, increasing the risk of heart disease. Interestingly in our study, RETN was associated with lower LDL-C, and this needs more attention in future studies to evaluate the effect of RETN on circulating lipids in healthy individuals because most of the previous studies were performed in obese or diabetics subjects.
TNFR1, TNFR2, and TRAIL-2 represent members of the TNF family of cytokines that induce apoptosis in a wide variety of cells, and according to STRING, they share some functional partners. For instance, TRADD, RIPK-1, and TRAF2 are all involved in response to tissue damage, regulation of cell survival, and apoptosis. Further, a predicted partner for RETN is glucocorticoid receptor (NR3C1), and glucocorticoids are potent inducers of apoptosis in many cell types and tissues. There were no functional partners identified by STRING for KIM-1; however, KIM-1 is a phosphatidylserine receptor that recognizes apoptotic cells and directs them to lysosomes. Taken together, it seems like proteins associated with all 4 lipid fractions in our study are involved in apoptosis. Although apoptosis is a normal mechanism for cellular turnover, it may be accelerated by cellular stresses caused by lipid accumulation. Lipotoxicity is an increased accumulation of lipid intermediates into nonadipose tissue, notably, skeletal muscle, liver, and heart, leading to cellular dysfunction and cell death, that is, lipoapoptosis. 46 Using orthogonal data, we indeed showed that genes encoding for TNFR1, TNFR2, and TRAIL-2 are expressed in heart, skeletal muscle, and liver.
Among proteins associated with higher TG and lower HDL-C, FABP4, tPA, and IL-1RA have been previously linked to IR measured by homeostasis model assessment in 2 community-based cohorts. 47 For the remaining 12 proteins showing this pattern, less is known about their relation to IR and dyslipidemia. That said, several proteins have known biology that could imply a role in IR. For example, IL-16 plays a role in initiating and sustaining an inflammatory response via stimulation of IL-1B and IL-6 expression in human monocytes. 48 Neutralization of IL-16 protects nonobese diabetic mice from autoimmune type 1 diabetes mellitus, 49 but more studies are needed to explain the association between TG, HDL-C, and IL-6 in general human population.
In MR analyses, we used genetic variants to explore possible causal effects of protein levels on lipid levels and we had at least 80% power to detect larger effects for most of the proteins. None of MR analyses revealed causal relationships, but there may still exist smaller causal effects than what we had no power to test for. We cannot rule out the possibility that lipid levels might be causal for protein levels because we were unable to test it because of lack of statistical power.
Strengths and Limitations
A major strength of the study is the design in which findings from the discovery cohort were confirmed in other general population-based cohorts. Moreover, with strict multipletesting correction, the risk of false-positive findings in the replication stage was calculated to 0.1%. Another strength is the large number of available protein biomarkers in all 3 cohorts (57 proteins), which allowed us for a comprehensive analysis. Moreover, in this study, we present not only an observational analysis, but we also attempted to investigate the causality between the observed associations. However, as a limitation of the MR analyses, there is a possibility that a nonsynonymous variant may affect binding of the proteindetecting antibodies, thus affecting the quantification. This could result in an invalid instrument because the instrument will not really reflect the protein levels but occurs as synthetic association because of a technical artifact. Although this risk is probably small, it has been reported for a genetic association study of adiponectin analyzed with ELISA. 50 We also want to acknowledge that in contrast to mass spectrometry methods, the Olink protein immunoassay does not allow profiling of different protein isoforms or posttranslational modifications. However, mass spectrometry methods have the limitation of lower throughput making it difficult to analyze samples from 3370 individuals.Finally, our study samples were middle aged to elderly and of Northern European descent, so the generalizability to other ethnicities and younger individuals is unknown.
Conclusions
In summary, we report a comprehensive lipid-protein association map, rich in cytokines, enzymes, receptors, and growth factors. Some of these proteins, such as KIM-1, RETN, TNFR1, TNFR2, and TRAIL-2, could be good candidates to follow-up in longitudinal studies to determine their ability to predict changes to lipid levels. Further future studies should address lipoapoptotic properties of these proteins, as well as potential causality of lipid metabolism on protein levels.
